TheraRadar
← Back
Data updated: Jun 28, 2026

AMICI PHARMA

Generics

AMICI PHARMA is a generic drug manufacturer focused on Immunology.

2004
Since
2
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

AMICI PHARMA's Key Drugs

AMICI PHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

AMICI PHARMA's Recent FDA Approvals

New NDA/BLA approvals for AMICI PHARMA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

AMICI PHARMA's Therapeutic Areas

AMICI PHARMA's approved drugs and pipeline span 1 therapeutic area, led by Immunology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Immunology 100%
1 drugs

AMICI PHARMA's Top Competitors

AMICI PHARMA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

AMICI PHARMA Pipeline Snapshot

Active clinical trials for AMICI PHARMA across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Immunology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling